Volume : 09, Issue : 12, December – 2022
Title:
14.AN OVERVIEW OF PREVENTING MEASURES TOWARD ANTIBIOTIC RESISTANCE, PHARMACIST’S ROLE
Authors :
Abdullah Mohammed Merai, Raied Mohammed Qohal, Mohammed morwie Ali Shaffie, Abdullah Mohammed Amry, Abdu Ahmed Almarshad, Fahad Abdu Essa Mutabi, Ibrahim Mohammed Safhi, Hassan suliman jubran harissa, Abdullmonem yahya ahmed al hadi, Ahmed Ibrahim Ahmed Ghazi
Abstract :
Antimicrobial stewardship (AMS) teams around the world include pharmacists, and their impact on this is unclear, therefore we aimed by this review to emphasizes their roles. We have conducted a search through electronic databases; Medline and Embase, for all relevant studies related to our topic which was published till the middle of 2022.
As antibiotic and vaccine regimens become more complex due to the continuously evolving epidemiology of infectious illnesses, the pharmacist’s involvement in battling and preventing infectious diseases is vital. The decline in medication development makes the preservation of already existing antibiotics of utmost importance, emphasizing the roles of pharmacists in optimizing the effectiveness of available treatments. While further training in infectious diseases may be required for certain pharmacist roles in preventing antibiotic resistance, there are numerous others that all pharmacists can assume.
Cite This Article:
Please cite this article in press Abdullah Mohammed Merai et al, An Overview Of Preventing Measures Toward Antibiotic Resistance, Pharmacist’s Role.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
1. Hammond, A., B. Stuijfzand, M.B. Avison, and A.D. Hay. 2020. Antimicrobial resistance associations with national primary care antibiotic stewardship policy: primary care-based, multilevel analytic study. PLoS One 15: e0232903.
2. Rathish, D., and N.D. Wickramasinghe. 2020. Prevalence, associated factors and reasons for antibiotic self-medication among dwellers in Anuradhapura: a community-based study. Int. J. Clin. Pharm. 42:1139–1144.
3. Hu, X.Y., M. Logue, and N. Robinson. 2020. Antimicrobial resistance is a global problem—a UK perspective. Eur. J. Integr. Med. 36:101136.
4. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.
5. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33(3):289-295.
6. Charani E, Cooke J, Holmes A. Antibiotic stewardship programmes–what’s missing? J Antimicrob Chemother. 2010;65(11):2275-2277.
7. Hall RG, 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121(6):515-518.
8. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1):82-98.
9. Bauer KA, West JE, Balada-Llasat JM, et al. An antimicrobial stewardship program’s impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis. 2010;51(9):1074-1080.
10. Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother. 2008;52(10):3558-3563.
11. Hansen E, Woods RJ, Read AF.. How to use a chemotherapeutic agent when resistance to it threatens the patient. PLoS Biol 2017;15:e2001110.
12. Goldstein EJC, Tyrrell KL, Citron DM.. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 2015;60:S98–107.
13. MacLean RC, Hall AR, Perron GG. et al. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat Rev Genet 2010;11:405–14.
14. Shields RK, Nguyen MH, Clancy CJ.. Clinical perspectives on echinocandin resistance among candida species. Curr Opin Infect Dis 2015;28:514–22.
15. Arendrup MC, Patterson TF.. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect 2017;216:S445–51.
16. Evers S, Casadewall B, Charles M. et al. Evolution of structure and substrate specificity in d-alanine: d-alanine ligases and related enzymes. J Mol Evol 1996;42:706–12.
17. Kinnear CL, Patel TS, Young CL. et al. Impact of an antimicrobial stewardship intervention on within- and between-group patient daptomycin resistance evolution in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2019;63:e1800–18.
18. Usacheva EA, Ginocchio CC, Morgan M. et al. Prospective, multicenter evaluation of the BD GeneOhmVanR assay for direct, rapid detection of vancomycin-resistant Enterococcus species in perianal and rectal specimens. Am J Clin Pathol 2010;134:219–26.
19. Morley VJ, Woods RJ, Read AF.. Bystander selection for antimicrobial resistance: implications for patient health. Trends Microbiol 2019;27:864–77.
20. Dubin KA, Mathur D, McKenney PT. et al. Diversification and evolution of vancomycin-resistant Enterococcus faecium during intestinal domination. Infect Immun 2019;87:e00102.
21. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 2015;109:309–18.
22. Xiao YH, Giske CG, Wei ZQ, et al.. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat 2011;14(4-5):236–50. 10.1016/j.drup.2011.07.001
23. World Health Organization. Global strategy for containment of antimicrobial resistance. 2001.
24. Zhang HX, Li X, Huo HQ, et al.. Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. PLoS One 2014;9:e88971 10.1371/journal.pone.0088971
25. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:CD003543 10.1002/14651858.CD003543.pub3
26. Ma X, Xie J, Yang Y, et al. Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center. BMC Infect Dis 2016;16:704 10.1186/s12879-016-2051-8.
27. Xu J, Duan X, Wu H, et al.. Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based study. PLoS One 2013;8:e78604 10.1371/journal.pone.0078604.
28. Horikoshi Y, Suwa J, Higuchi H, et al.. Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality. Int J Infect Dis 2017;64:69–73. 10.1016/j.ijid.2017.09.012
29. Bao L, Peng R, Wang Y, et al.. Significant reduction of antibiotic consumption and patients’ costs after an action plan in China, 2010-2014. PLoS One 2015;10:e0118868 10.1371/journal.pone.0118868.
30. Bao L, Peng R, Wang Y, et al.. Significant reduction of antibiotic consumption and patients’ costs after an action plan in China, 2010-2014. PLoS One 2015.
31. Bratzler DW, Dellinger EP, Olsen KM, et al.. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195–283. 10.2146/ajhp120568
32. Charbonneau P, Parienti JJ, Thibon P, et al.. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006;42:778–84. 10.1086/500319
33. Weber SG, Gold HS, Hooper DC, et al.. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415–22. 10.3201/eid0911.030284
34. Aldeyab MA, Scott MG, Kearney MP, et al.. Impact of an enhanced antibiotic stewardship on reducing methicillin-resistant Staphylococcus aureus in primary and secondary healthcare settings. Epidemiol Infect 2014;142:494–500. 10.1017/S0950268813001374
35. Lawes T, Edwards B, López-Lozano JM, et al.. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006-2010: retrospective cohort study and time-series intervention analysis. BMJ Open 2012;2:e000797 10.1136/bmjopen-2011-000797.
2. Rathish, D., and N.D. Wickramasinghe. 2020. Prevalence, associated factors and reasons for antibiotic self-medication among dwellers in Anuradhapura: a community-based study. Int. J. Clin. Pharm. 42:1139–1144.
3. Hu, X.Y., M. Logue, and N. Robinson. 2020. Antimicrobial resistance is a global problem—a UK perspective. Eur. J. Integr. Med. 36:101136.
4. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.
5. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33(3):289-295.
6. Charani E, Cooke J, Holmes A. Antibiotic stewardship programmes–what’s missing? J Antimicrob Chemother. 2010;65(11):2275-2277.
7. Hall RG, 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121(6):515-518.
8. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1):82-98.
9. Bauer KA, West JE, Balada-Llasat JM, et al. An antimicrobial stewardship program’s impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis. 2010;51(9):1074-1080.
10. Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother. 2008;52(10):3558-3563.
11. Hansen E, Woods RJ, Read AF.. How to use a chemotherapeutic agent when resistance to it threatens the patient. PLoS Biol 2017;15:e2001110.
12. Goldstein EJC, Tyrrell KL, Citron DM.. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 2015;60:S98–107.
13. MacLean RC, Hall AR, Perron GG. et al. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat Rev Genet 2010;11:405–14.
14. Shields RK, Nguyen MH, Clancy CJ.. Clinical perspectives on echinocandin resistance among candida species. Curr Opin Infect Dis 2015;28:514–22.
15. Arendrup MC, Patterson TF.. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect 2017;216:S445–51.
16. Evers S, Casadewall B, Charles M. et al. Evolution of structure and substrate specificity in d-alanine: d-alanine ligases and related enzymes. J Mol Evol 1996;42:706–12.
17. Kinnear CL, Patel TS, Young CL. et al. Impact of an antimicrobial stewardship intervention on within- and between-group patient daptomycin resistance evolution in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2019;63:e1800–18.
18. Usacheva EA, Ginocchio CC, Morgan M. et al. Prospective, multicenter evaluation of the BD GeneOhmVanR assay for direct, rapid detection of vancomycin-resistant Enterococcus species in perianal and rectal specimens. Am J Clin Pathol 2010;134:219–26.
19. Morley VJ, Woods RJ, Read AF.. Bystander selection for antimicrobial resistance: implications for patient health. Trends Microbiol 2019;27:864–77.
20. Dubin KA, Mathur D, McKenney PT. et al. Diversification and evolution of vancomycin-resistant Enterococcus faecium during intestinal domination. Infect Immun 2019;87:e00102.
21. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 2015;109:309–18.
22. Xiao YH, Giske CG, Wei ZQ, et al.. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat 2011;14(4-5):236–50. 10.1016/j.drup.2011.07.001
23. World Health Organization. Global strategy for containment of antimicrobial resistance. 2001.
24. Zhang HX, Li X, Huo HQ, et al.. Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. PLoS One 2014;9:e88971 10.1371/journal.pone.0088971
25. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:CD003543 10.1002/14651858.CD003543.pub3
26. Ma X, Xie J, Yang Y, et al. Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center. BMC Infect Dis 2016;16:704 10.1186/s12879-016-2051-8.
27. Xu J, Duan X, Wu H, et al.. Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based study. PLoS One 2013;8:e78604 10.1371/journal.pone.0078604.
28. Horikoshi Y, Suwa J, Higuchi H, et al.. Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality. Int J Infect Dis 2017;64:69–73. 10.1016/j.ijid.2017.09.012
29. Bao L, Peng R, Wang Y, et al.. Significant reduction of antibiotic consumption and patients’ costs after an action plan in China, 2010-2014. PLoS One 2015;10:e0118868 10.1371/journal.pone.0118868.
30. Bao L, Peng R, Wang Y, et al.. Significant reduction of antibiotic consumption and patients’ costs after an action plan in China, 2010-2014. PLoS One 2015.
31. Bratzler DW, Dellinger EP, Olsen KM, et al.. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195–283. 10.2146/ajhp120568
32. Charbonneau P, Parienti JJ, Thibon P, et al.. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006;42:778–84. 10.1086/500319
33. Weber SG, Gold HS, Hooper DC, et al.. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415–22. 10.3201/eid0911.030284
34. Aldeyab MA, Scott MG, Kearney MP, et al.. Impact of an enhanced antibiotic stewardship on reducing methicillin-resistant Staphylococcus aureus in primary and secondary healthcare settings. Epidemiol Infect 2014;142:494–500. 10.1017/S0950268813001374
35. Lawes T, Edwards B, López-Lozano JM, et al.. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006-2010: retrospective cohort study and time-series intervention analysis. BMJ Open 2012;2:e000797 10.1136/bmjopen-2011-000797.